Biotech

All Articles

Pfizer takes $230M hit after axing failed DMD gene treatment

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) gene therapy breakdown has blown a $230 million h...

AC Immune views 'spots' potential in Alzheimer's medication records

.After much more than twenty years of work on neurodegenerative ailments, Swiss biotech air conditio...

GSK falls ph. 2 HPV vaccine over lack of best-in-class potential

.GSK has actually scrapped a phase 2 individual papillomavirus (HPV) vaccine from its own pipeline a...

OS Treatments refiles $6M IPO to fund HER2 drug, preclinical ADCs

.OS Therapies are going to detail on the NYSE American sell swap today using a $6.4 thousand IPO tha...

ALX's waning CD47 feedback rate delivers sell spiraling down

.ALX Oncology's period 2 gastric cancer response rate has actually deteriorated. After seeing its CD...

Ionis centers eye ailment coming from targets of Roche-partnered possibility after information disappoint

.One More of Ionis Pharmaceuticals' crucial midphase readouts has actually disappointed assumptions,...

Biogen's CEO mentioned no high-risk handle 2023. He prepares to be vibrant

.While Biogen's pharma peers are seeking for late-stage possessions with little bit of danger, CEO C...

Instil refills pipeline in $2B biobucks manage ImmunOnco

.Instil Biography has actually been a biotech searching for a pipe after it scrapped its own lead po...

Biogen ignores Denali Alzheimer's collab

.Biogen has handed back liberties to a very early Alzheimer's health condition plan to Denali Therap...

Takeda touches brand new mind people oncology service-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and ...